- Home
- FEMY vs ANVS Comparison
FEMY vs ANVS Comparison
Compare FEMY & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- ANVS
- Stock Information
- Founded
- FEMY 2004
- ANVS 2008
- Country
- FEMY United States
- ANVS United States
- Employees
- FEMY N/A
- ANVS N/A
- Industry
- FEMY Medical/Dental Instruments
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- ANVS Health Care
- Exchange
- FEMY Nasdaq
- ANVS Nasdaq
- Market Cap
- FEMY 31.9M
- ANVS 44.6M
- IPO Year
- FEMY 2021
- ANVS 2020
- Fundamental
- Price
- FEMY $0.93
- ANVS $2.36
- Analyst Decision
- FEMY Strong Buy
- ANVS Strong Buy
- Analyst Count
- FEMY 3
- ANVS 4
- Target Price
- FEMY $8.67
- ANVS $18.00
- AVG Volume (30 Days)
- FEMY 393.5K
- ANVS 485.7K
- Earning Date
- FEMY 08-07-2025
- ANVS 08-14-2025
- Dividend Yield
- FEMY N/A
- ANVS N/A
- EPS Growth
- FEMY N/A
- ANVS N/A
- EPS
- FEMY N/A
- ANVS N/A
- Revenue
- FEMY $1,699,232.00
- ANVS N/A
- Revenue This Year
- FEMY $231.84
- ANVS N/A
- Revenue Next Year
- FEMY $245.28
- ANVS N/A
- P/E Ratio
- FEMY N/A
- ANVS N/A
- Revenue Growth
- FEMY 61.97
- ANVS N/A
- 52 Week Low
- FEMY $0.69
- ANVS $1.11
- 52 Week High
- FEMY $1.80
- ANVS $17.88
- Technical
- Relative Strength Index (RSI)
- FEMY 48.34
- ANVS 48.29
- Support Level
- FEMY $0.85
- ANVS $2.05
- Resistance Level
- FEMY $0.99
- ANVS $3.18
- Average True Range (ATR)
- FEMY 0.07
- ANVS 0.26
- MACD
- FEMY 0.01
- ANVS -0.08
- Stochastic Oscillator
- FEMY 32.40
- ANVS 27.43
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.